UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE TITLE PAGES:

In Item [56] References Cited, in OTHER PUBLICATIONS:
in Venturoli et al., please replace "Prospectiove" with --Prospective--

IN THE SPECIFICATION:

At column 5, line 20, please replace structure

"



"

with the following structure: --



--

At column 9, line 34, please replace "A R^9" with --R^9--

At column 31, line 56-67, please replace structure

"



34

"

with the following structure: --



34

--

CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE CLAIMS:

Column 79, line 40 thru Column 81, line 37 (Claim 1) should read

Please replace Claims 1, 10, 24, 40, 57, and 58 with the following Claims:

1. A compound having the formula:



(I)

wherein:

R^1 is selected from the group consisting of hydrogen, F, Cl, Br, I, NO_2, OR^9, $NR^{10}R^{11}$, $S(O)_nR^9$, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2–C_8 alkynyl and optionally substituted C_2–C_8 alkenyl;

R^2 is selected from the group consisting of hydrogen, F, Cl, Br, I, CF_3, CF_2Cl, CF_2H, CFH_2, CF_2OR^9, CH_2OR^9, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2–C_8 alkynyl and optionally substituted C_2–C_8 alkenyl;

R^3 and R^4 each independently is selected from the group consisting of hydrogen, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$, $CNR^{10}R^{11}$, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2–C_8 alkynyl and optionally substituted C_2–C_8 alkenyl;

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R^5 and R^6 each independently is selected from the group consisting of hydrogen, CF_3, CF_2Cl, CF_2H, CFH_2, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2–C_8 alkynyl and optionally substituted C_2–C_8 alkenyl;

R^7 is selected from the group consisting of hydrogen, F, Cl, Br, I, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$ and $C(Y)NR^{10}R^{11}$;

R^8 is selected from the group consisting of hydrogen, F, Cl, Br, I, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$ and $C(Y)NR^{10}R^{11}$;

R^9 is selected from the group consisting of hydrogen, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted arylalkyl;

R^{10} is selected from the group consisting of hydrogen, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, CO_2R^{12}, $C(O)R^{12}$, SO_2R^{12} and $S(O)R^{12}$;

R^{11} and R^{12} each independently is selected from the group consisting of hydrogen, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted arylalkyl;

R^{13} is selected from the group consisting of optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_2–C_8 alkenyl, optionally substituted C_2–C_8 alkynyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl;

m is selected from the group consisting of 0, 1 and 2;

n is selected from the group consisting of 0, 1 and 2;

W is selected from the group consisting of NH, $N\{R^{13}\}$, $N\{C(Y)R^{11}\}$ and $N\{SO_2R^{11}\}$;

X is O;

Z is selected from the group consisting of NH, $N\{R^{11}\}$, $N\{C(Y)R^{11}\}$, $N\{SO_2R^{12}\}$ and $N\{S(O)R^{12}\}$; and

Y is O;

and pharmaceutically acceptable salts thereof; wherein:

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

the substituents of an optionally substituted group comprise one or more substituents independently selected from among alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkoxy, aryloxy, haloalkoxy, amino, alkylamino, dialkylamino, alkylthio, arylthio, heteroarylthio, oxo, carboxyester, carboxamido, acyloxy, hydrogen, F, Cl, Br, I, CN, NO_2, NH_2, N_3, $NHCH_3$, $N(CH_3)_2$, SH, SCH_3, OH, OCH_3, OCF_3, CH_3, CF_3, $C(O)CH_3$, CO_2CH_3, CO_2H, $C(O)NH_2$, OR^9, SR^9, $NR^{10}R^{11}$, CF_2CF_3, CH_2CH_2F and CH_2CF_3.

Column 82, lines 6-58, Claim 10 should read

10. The compound of claim 1, wherein:

R^1 is selected from the group consisting of hydrogen, F, Cl, Br, I, NO_2, OR^9, $NR^{10}R^{11}$, $S(O)_nR^9$, C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, C_3–C_8 cycloalkyl, aryl, arylalkyl, heteroaryl, C_2–C_8 alkynyl and C_2–C_8 alkenyl;

R^2 is selected from the group consisting of hydrogen, F, Cl, Br, I, CF_3, CF_2Cl, CF_2H, CFH_2, CF_2OR^9, CH_2OR^9, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, C_3–C_8 cycloalkyl, aryl, arylalkyl, heteroaryl, C_2–C_8 alkynyl and C_2–C_8 alkenyl;

R^3 and R^4 each independently is selected from the group consisting of hydrogen, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$, $C(Y)NR^{10}R^{11}$, C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, C_3–C_8 cycloalkyl, aryl, arylalkyl, heteroaryl, C_2–C_8 alkynyl and C_2–C_8 alkenyl;

R^5 and R^6 each independently is selected from the group consisting of hydrogen, CF_3, CF_2Cl, CF_2H, CFH_2, C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, C_3–C_8 cycloalkyl, aryl, arylalkyl, heteroaryl, C_2–C_8 alkynyl and C_2–C_8 alkenyl;

R^7 is selected from the group consisting of hydrogen, F, Cl, Br, I, C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, aryl, heteroaryl, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$ and $C(Y)NR^{10}R^{11}$;

R^8 is selected from the group consisting of hydrogen, F, Cl, Br, I, C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, aryl, heteroaryl, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$ and $C(Y)NR^{10}R^{11}$;

R^9 is selected from the group consisting of hydrogen, C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, aryl, heteroaryl and arylalkyl;

R^{10} is selected from the group consisting of hydrogen, C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, aryl, heteroaryl, arylalkyl, CO_2R^{12}, $C(O)R^{12}$, SO_2R^{12} and $S(O)R^{12}$;

R^{11} and R^{12} each independently is selected from the group consisting of hydrogen, C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, aryl, heteroaryl, arylalkyl;

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R^{13} is selected from the group consisting of C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, C_2–C_8 alkenyl, C_2–C_8 alkynyl, C_3–C_8 cycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;

m is selected from the group consisting of 0, 1 and 2;

n is selected from the group consisting of 0, 1 and 2;

W is selected from the group consisting of NH, $N\{R^{13}\}$, $N\{C(Y)R^{11}\}$ and $N\{SO_2R^{11}\}$;

X is O;

Z is selected from the group consisting of NH, $N\{R^{11}\}$, $N\{C(Y)R^{11}\}$, $N\{SO_2R^{12}\}$ and $N\{S(O)R^{12}\}$; and

Y is O;

and pharmaceutically acceptable salts thereof.

Column 83, lines 53-55 Claim 24 should read

24. A compound according to claim 23, wherein R^9 is selected from the group consisting of hydrogen and optionally substituted C_1–C_4 alkyl.

Column 85, line 20 thru column 86, line 64 Claim 40 should read

40. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula:



(I)

wherein:

R^1 is selected from the group consisting of hydrogen, F, Cl, Br, I, NO_2, OR^9, $NR^{10}R^{11}$, $S(O)_nR^9$, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2–C_8 alkynyl and optionally substituted C_2–C_8 alkenyl;

R^2 is selected from the group consisting of hydrogen, F, Cl, Br, I, CF_3, CF_2Cl, CF_2H, CFH_2, CF_2OR^9, CH_2OR^9, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2–C_8 alkynyl and optionally substituted C_2–C_8 alkenyl;

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R^3 and R^4 each independently is selected from the group consisting of hydrogen, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$, $C(Y)NR^{10}R^{11}$, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2–C_8 alkynyl and optionally substituted C_2–C_8 alkenyl;

R^5 and R^6 each independently are selected from the group consisting of hydrogen, CF_3, CF_2Cl, CF_2H, CFH_2, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2–C_8 alkynyl and optionally substituted C_2–C_8 alkenyl;

R^7 is selected from the group consisting of hydrogen, F, Cl, Br, I, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$ and $C(Y)NR^{10}R^{11}$;

R^8 is selected from the group consisting of hydrogen, F, Cl, Br, I, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$ and $C(Y)NR^{10}R^{11}$;

R^9 is selected from the group consisting of hydrogen, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted arylalkyl;

R^{10} is selected from the group consisting of hydrogen, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, CO_2R^{12}, $C(O)R^{12}$, SO_2R^{12} and $S(O)R^{12}$;

R^{11} and R^{12} each independently is selected from the group consisting of hydrogen, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted arylalkyl;

R^{13} is selected from the group consisting of optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_2–C_8 alkenyl, optionally substituted C_2–C_8 alkynyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl;

m is 1;

n is selected from the group consisting of 0, 1 and 2;

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

W is selected from the group consisting of NH, N{R^{13}}, N{C(Y)R^{11}} and N{SO_2R^{11}};

X is O;

Z is selected from the group consisting of NH, N{R^{11}}, N{C(Y)R^{11}}, N{SO_2R^{12}} and N{S(O)R^{12}}; and

Y is O;

and pharmaceutically acceptable salts thereof; wherein:

the substituents of an optionally substituted group comprise one or more substituents independently selected from among alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkoxy, aryloxy, haloalkoxy, amino, alkylamino, dialkylamino, alkythio, arylthio, heteroarylthio, oxo, carboxyester, carboxamido, acyloxy, hydrogen, F, Cl, Br, I, CN, NO_2, NH_2, N_3, $NHCH_3$, $N(CH_3)_2$, SH, SCH_3, OH, OCH_3, OCF_3, CH_3, CF_3, $C(O)CH_3$, CO_2CH_3, CO_2H, $C(O)NH_2$, OR^9, SR^9, $NR^{10}R^{11}$, CF_2CF_3, CH_2CH_2F and CH_2CF_3.

Column 88, line 27 thru Column 90, line 35, Claim 57 should read

57. A compound selected from the group consisting of:

(3*R*)-2,3,4,7-Tetrahydro-3-methyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-2,3,4,7-Tetrahydro-3,4-dimethyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-4-Ethyl-2,3,4,7-tetrahydro-3-methyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-2,3,4,7-Tetrahydro-3-methyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-2,3,4,7-Tetrahydro-3-methyl-4-propyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-4-Allyl-2,3,4,7-tetrahydro-3-methyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-3-Ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-3-Ethyl-2,3,4,7-tetrahydro-4-methyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-3,4-Diethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-3-Ethyl-2,3,4,7-tetrahydro-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-4-(2-Chloro-2,2-difluoroethyl)-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(3*R*)-4-(2,2-Difluoroethyl)-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-3-Ethyl-2,3,4,7-tetrahydro-4-propyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-4-Allyl-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-3-Ethyl-2,3,4,7-tetraydro-4-isobutyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R/S*)-2,3,4,7-Tetrahydro-3-propyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R/S*)-2,3,4,7-Tetrahydro-4-methyl-3-propyl-10-(trifluoromethyl)-8*H*[1,4]oxazino-[2,3-*f*]quinolin-8-one;

(3*R/S*)-4-Ethyl-2,3,4,7-tetrahydro-3-propyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R/S*)-2,3,4,7-Tetrahydro-3-propyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-2,3,4,7-Tetrahydro-3-isopropyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-2,3,4,7-Tetrahydro-3-isopropyl-4-methyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino-[2,3-*f*]quinolin-8-one;

(3*R*)-4-Ethyl-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino-[2,3-*f*]quinolin-8-one;

(3*R*)-2,3,4,7-Tetrahydro-3-isopropyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-4-(2-Chloro-2,2-difluoroethyl)-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-4-(2,2-Difluoroethyl)-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-4-Allyl-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino-[2,3-*f*]quinolin-8-one;

(3*R*)-2,3,4,7-Tetrahydro-3-phenyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-2,3,4,7-Tetrahydro-3-phenyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-4-Cyclopropylmethyl-2,3,4,7-tetrahydro-3-phenyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-3-Benzyl-2,3,4,7-tetrahydro-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

2,3,4,7-Tetrahydro-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

2,3,4,7-tetrahydro-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8*H*-[1,4]oxazino [2,3-*f*]quinolin-8-one;

(7a*R*,10a*S*)-7,7a,8,9,10,10a-Hexahydro-1-(trifluoromethyl) -7-(2,2,2-trifluoroethyl)-4*H*-cyclopenta[5,6][1,4]oxazino[2,3-*f*]quinolin-3-one;

(7a*R*,10a*S*)-7-Ethyl-7,7a,8,9,10,10a-hexahydro-1-(trifluoromethyl) -4*H*-cyclopenta-[5,6][1,4]oxazino[2,3-*f*]quinolin-3-one;

(7a*R*,10a*S*)-7,7a,8,9,10,10a-Hexahydro-3-isopropoxy-1-(trifluoromethyl) -7-(2,2,2-trifluoroethyl)-4*H*-cyclopenta[5,6][1,4]oxazino[2,3-*f*]quinolin-3-one;

(±)-(2*S*,3*R*)-2,3,4,7-Tetrahydro-2,3-dimethyl-4-(2,2,2-trifluoroethyl) -10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(6a*R*)-6a,7,8,9-Tetrahydro-4-(trifluoromethyl)-1*H*,6*H*-pyrrolo[1',2':4,5][1,4] -oxazino[2,3-*f*]quinolin-2-one;

2,3,4,7-Tetrahydro-2,2,4-trimethyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino [2,3-*f*]-quinolin-8-one;

(3*R*)-8-Chloro-3-ethyl-3,4-dihydro-8-isopropoxy-4-(2,2,2-trifluoroethyl) -10-(trifluoromethyl)-2*H*-[1,4]oxazino[2,3-*f*]quinoline;

(3*R*)-3-Ethyl-3,4-dihydro-8-isopropoxy-8-methoxy-4-(2,2,2-trifluoroethyl) -10-(trifluoromethyl)-2*H*-[1,4]oxazino[2,3-*f*]quinoline;

(±)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(–)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(+)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(±)-2,3,4,7-Tetrahydro-3-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8*H*-[1,4] oxazino[2,3-*f*]quinolin-8-one;

(±)-2,3,4,7-Tetrahydro-4-methyl-3-(2,2,2-trifluoroethyl)-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(±)-4-Ethyl-2,3,4,7-tetrahydro-3-(2,2,2-trifluoroethyl)-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(±)-2,3,4,7-Tetrahydro-3,4-bis(2,2,2-trifluoroethyl)-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(-)-2,3,4,7-Tetrahydro-3,4-bis(2,2,2-trifluoroethyl)-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(+)-2,3,4,7-Tetrahydro-3,4-bis(2,2,2-trifluoroethyl)-10-(trifluoromethyl -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±)-4-Cyclopropylmethyl-2,3,4,7-tetrahydro-3-(2,2,2-trifluoroethyl) -10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(3*R*)-4-Cyclopropylmethyl-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(3*R*)-4-(2-Chloroethyl)-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(±)-2,3,4,7-Tetrahydro-2-methyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(3*R*)-3-Ethyl-4-(2-hydroxy-2-methylpropyl)-2,3,4,7-tetrahydro -10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one; and
(3*R*)-2,3,4,7-Tetrahydro-3-isobutyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one; and
pharmaceutically acceptable salts thereof.

Column 90, line 35 thru Column 92, line 4 Claim 58 should read
58. A compound selected from the group consisting of:
(3*R*)-2,3,4,7-Tetrahydro-3-methyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(3*R*)-3-Ethyl-2,3,4,7-tetrahydro-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(3*R*)-4-(2-Chloro-2,2-difluoroethyl)-3-ethyl-2,3,4,7-tetrahydro -10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(3*R*)-4-(2,2-Difluoroethyl)-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(3*R*)-2,3,4,7-Tetrahydro-3-isopropyl-4-(2,2,2-trifluoroethyl) -10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(3*R*)-4-(2-Chloro-2,2-difluoroethyl)-2,3,4,7-tetrahydro-3-isopropyl -10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(3*R*)-4-(2,2-Difluoroethyl)-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(7a*R*,10a*S*)-7-Ethyl-7,7a,8,9,10,10a-hexahydro-1-(trifluoromethyl -4*H*-cyclopenta[5,6][1,4]oxazino[2,3-*f*]quinolin-3-one;
(7a*R*,10a*S*)-7-7a,8,9,10,10a-Hexahydro-1-(trifluoromethyl) -7-(2,2,2-trifluoroethyl)-4*H*-cyclopenta[5,6][1,4]oxazino[2,3-*f*]quinolin-3-one;
(±)-(2*S*,3*R*)-2,3,4,7-Tetrahydro-2,3-dimethyl-4-(2,2,2-trifluoroethyl) -10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(±)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(–)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one; and
(+)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-one; and
pharmaceutically acceptable salts thereof.

This certificate supersedes the Certificate of Correction issued June 17, 2008.

Signed and Sealed this

Twenty-second Day of July, 2008



JON W. DUDAS
Director of the United States Patent and Trademark Office